Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

16.47 -0.64 (-3.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Arcutis Biotherapeutics: Q1 Earnings Insights
Via Benzinga
Global Payments, MGM Resorts And 3 Stocks To Watch Heading Into Monday
With US stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Where Arcutis Biotherapeutics Stands With Analysts
Via Benzinga
Arcutis Biotherapeutics's Earnings Outlook
Via Benzinga
Arcutis' Flagship Psoriasis Treatment Shows Sustained Efficacy, Clearance For Median Of 10 Months
Via Benzinga
Arcutis Biotherapeutics Stock Surges After Successful Atopic Dermatitis Trial
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) announced topline results from its INTEGUMENT-1 pivotal Phase 3 trial of roflumilast cream 0.15% for mild to moderate atopic dermatitis.  
Via Benzinga
Arcutis Shares Gain On Positive Phase 3 Data On Roflumilast Foam In Scalp, Body Psoriasis
Via Benzinga
Atopic Dermatitis Player Arcutis Scoops Up DucentisBioTherapeutics
Via Benzinga
Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing
Biotech stocks were hammered Wednesday, including several that had good news. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
What 4 Analyst Ratings Have To Say About Arcutis Biotherapeutics
Over the past 3 months, 4 analysts have published their opinion on Arcutis Biotherapeutics (NASDAQ:ARQT) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022
Upgrades 
Via Benzinga
Why PolyPid Dipped Over 73%; Here Are 60 Biggest Movers From Friday
Gainers Venus Concept Inc. (NASDAQ: VERO) jumped 54.9% to settle at $0.5419 on Friday. The company, last month, posted downbeat quarterly results. 
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Arcutis Concludes Dosing In Late-Stage Itchy Skin Study, Anticipates Regulatory Submission By Next Year
Arcutis Biotherapeutics (NASDAQ: ARQT) has completed the enrollment of subject in its INTEGUMENT-2 pivotal Phase 3 trial of roflumilast cream 0.15% in adults and children with Atopic dermatitis (AD). 
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients... 
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume. 
Via Benzinga
Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday. 
Via Benzinga
Analyst Ratings for Arcutis Biotherapeutics
Over the past 3 months, 4 analysts have published their opinion on Arcutis Biotherapeutics (NASDAQ:ARQT) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday
Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around 18% on Friday. 
Via Benzinga
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap Of Friday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Arcutis Gets FDA Nod For Plaque Psoriasis Candidate, Sees Commercial Launch In Mid-August
The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ: ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in... 
Via Benzinga
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
7 Biotech Stocks to Buy for Q3
These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. 
Via InvestorPlace
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
Via Benzinga
Mizuho Sees Buying Opportunity Despite Weakness In This Skin-Disease Focused Stock
Mizuho remains bullish on Arcutis Biotherapeutics Inc (NASDAQ: ARQT). It sees buying opportunity in the weakness as the company heads into 2H of 2022 with four potentially transformative catalysts for... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.